Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03938389 · ClinicalTrials.gov registry record · Phase 4

The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans

A Phase 4 study of Obesity and Blood Pressure, sponsored by Ohio State University.

Active
Registry status
Phase 4
Development phase
90
Enrollment target
1
Study location

NCT03938389 is a Phase 4 study of Obesity and Blood Pressure that is active but no longer recruiting, run by Ohio State University. The registered enrollment target is 90 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03938389, a Phase 4 study of Obesity and Blood Pressure, is active but no longer recruiting, sponsored by Ohio State University.

ACTIVE NOT RECRUITING
Registry status
Phase 4
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition (valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the pancreas over 26 weeks assessed with glucose clamp studies among African Americans (AAs) with impaired glucose tolerance. The investigators hypothesize that combined RAAS/neprilysin inhibition will lead to greater improvement in insulin release from the pancreas and improved blood sugar compared to RAAS inhibition alone among AAs with impaired glucose tolerance.

Conditions Studied

Obesity Blood Pressure PreDiabetes Impaired Glucose Tolerance

Interventions

  • DRUG Placebo Oral Tablet
  • DRUG Sacubitril-Valsartan Tab 97-103 MG
  • DRUG Valsartan 160mg

Study Locations (1)

Ohio

  • The Ohio State University Wexner Medical Center - Columbus

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2020-02-25
Est. Completion 2026-06
Phase Phase 4

Sponsor

Ohio State University

552 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03938389

The ClinicalTrials.gov registry entry for NCT03938389 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (89% lower). The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo Oral Tablet is the first listed.

NCT03938389 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03938389 about?

NCT03938389 is a clinical study titled "The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans". The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition (valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the pancreas over 26 weeks assessed with g...

What is the current status of trial NCT03938389?

This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2020-02-25. Estimated completion is 2026-06.

What conditions does trial NCT03938389 study?

This clinical trial studies the following conditions: Obesity, Blood Pressure, PreDiabetes, Impaired Glucose Tolerance.

What interventions are being tested in trial NCT03938389?

The interventions under investigation include: Placebo Oral Tablet (DRUG), Sacubitril-Valsartan Tab 97-103 MG (DRUG), Valsartan 160mg (DRUG).

Who is sponsoring clinical trial NCT03938389?

This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03938389 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Blood Pressure

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.